Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in treatm... von Bazinet, M, Pantea, V, Placinta, G, Moscalu, I, Cebotarescu, V, Cojuhari, L, Jimbei, P, Iarovoi, L, Smesnoi, V, Musteata, T, Jucov, A, Krawczyk, A, Vaillant, A

Volltext

FRI-343 - Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pe... von Vaillant, A., Bazinet, M., Pantea, V., Placinta, G., Moscalu, I., Cebotarescu, V., Cojuhari, L., Jimbei, P., Iarovoi, L., Smesnoi, V., Musteata, T., Jucov, A., Krawczyk, A.

Volltext

Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and pegylated in... von Vaillant, A., Bazinet, M., Pantea, V., Placinta, G., Moscalu, I., Cebotarescu, V., Cojuhari, L., Jimbei, P., Iarovoi, L., Smesnoi, V., Musteata, T., Jucov, A., Krawczyk, A.

Volltext

THU-154 - Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a... von Bazinet, M., Pantea, V., Placinta, G., Moscalu, I., Cebotarescu, V., Cojuhari, L., Jimbei, P., Iarovoi, L., Smesnoi, V., Musteata, T., Jucov, A., Krawczyk, A., Vaillant, A.

Volltext